Rapport TherapeuticsRAPP
13F holders, Q2 2024 (June 30)35holders
3famous investors
$23.22avg. 13F price*
At the end of Q2 2024, 35 institutions reported holding Rapport Therapeutics Inc. (RAPP) in their 13F filings. The largest holders were FMR LLC ($115.9M), ARCH Venture Management, LLC ($86.7M) and Cormorant Asset Management, LP ($68.4M). 3 famous investors held it, including George Soros (0.0% of Soros Fund Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Rapport Therapeutics Inc.
- CUSIP
- 75383L102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 36 | $593.4M |
| Exits | 0 | $0 |
Ownership 35 holders
| FMR LLC | 0.01% | New | 4,983,351 | $115.9M |
| ARCH Venture Management, LLC | 32.60% | New | 3,728,738 | $86.7M |
| Cormorant Asset Management, LP | 3.98% | New | 2,940,283 | $68.4M |
| Capital International Investors | 0.01% | New | 2,602,531 | $60.5M |
| Johnson & Johnson | 14.50% | New | 2,498,051 | $58.1M |
| Sofinnova Investments, Inc. | 2.86% | New | 1,951,562 | $45.4M |
| T. Rowe Price Investment Management, Inc. | 0.02% | New | 1,535,151 | $35.7M |
| T. Rowe Price Associates Inc. | 0.00% | New | 1,360,605 | $31.6M |
| Alliancebernstein L.P. | 0.01% | New | 1,090,858 | $25.4M |
| Perceptive Advisors LLC | 0.42% | New | 748,183 | $17.4M |
| Citadel Advisors | 0.01% | New | 592,458 | $13.2M |
| Artal Group S.A. | 0.21% | New | 350,000 | $8.1M |
| Logos Global Management LP | 0.50% | New | 208,910 | $4.4M |
| Woodline Partners LP | 0.04% | New | 171,100 | $4.0M |
| Millennium Management | 0.00% | New | 116,782 | $2.7M |
| TD Asset Management Inc | 0.00% | New | 101,522 | $2.4M |
| Manufacturers Life Insurance Company, The | 0.00% | New | 75,516 | $1.8M |
| Saturn V Capital Management LP | 0.62% | New | 70,000 | $1.6M |
| Norges Bank | 0.00% | New | 70,000 | $1.6M |
| Vanguard Group Inc. | 0.00% | New | 70,000 | $1.6M |
| LMR Partners LLP | 0.03% | New | 50,000 | $1.2M |
| Eventide Asset Management, LLC | 0.02% | New | 50,000 | $1.2M |
| Monashee Investment Management LLC | 0.12% | New | 40,000 | $930K |
| Alyeska Investment Group, L.P. | 0.00% | New | 34,731 | $808K |
| Soros Fund Management | 0.02% | New | 30,000 | $698K |
| Acuta Capital Partners, LLC | 0.39% | New | 20,000 | $465K |
| Squarepoint Ops LLC | 0.00% | New | 16,345 | $380K |
| Two Sigma Investments, LP | 0.00% | New | 13,000 | $302K |
| Balyasny Asset Management L.P. | 0.00% | New | 10,000 | $233K |
| Davidson Kempner Capital Management LP | 0.01% | New | 10,000 | $229K |
| Barclays PLC | 0.00% | New | 9,400 | $219K |
| Sandia Investment Management LP | 0.15% | New | 5,000 | $116K |
| UBS Group AG | 0.00% | New | 3,127 | $73K |
| Tidemark, LLC | 0.01% | New | 1,088 | $25K |
| Royal Bank of Canada | 0.00% | New | 225 | $5K |
"% of holder's portfolio" is RAPP's weight in each manager's 13F, not the share of Rapport Therapeutics Inc. the manager owns.